NCT06474286Not yet recruiting
Prucalopride for Cognitive Functioning in Schizophrenia
A Pilot Study to Assess the Effect of Prucalopride on Cognitive Functioning in Patients With Schizophrenia
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
A core component of schizophrenia is neurocognitive impairment. The cognitive deficits are prominently seen in memory, attention, working memory, problem solving, processing speed and social cognition. Atypical antipsychotics continue to be the mainstay of treatment in schizophrenia. Promising areas for future research include search for new compounds for cognition enhancement. Prucalopride, a highly selective 5HT4 receptor agonist is a potential drug and its effect on cognition in patients with schizophrenia needs to be studied. An open label, pilot study involving 34 patients with schizophrenia diagnosed as per DSM 5 criteria. The participants will receive Tab. Prucalopride one milligram (1 mg) for a duration of four weeks along with their existing treatment regimen with antipsychotics. Assessments includes PANSS and BACS at baseline and at the end of 4 weeks. The effect of prucalopride on cognitive functioning in patients with schizophrenia is studied.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- First submitted
- 18 Jun 2024
- Start date
- 31 May 2027
- Primary completion date
- 31 May 2028
- Lead sponsor
- University of Pittsburgh
- Diseases
- Schizophrenia
- NCT number
- NCT06474286
What you commit to
- Study type: Interventional
- Planned participants: 34
- From 31 May 2027 to the primary completion date, 31 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants administered MECT (modified electroconvulsive therapy)
- Use of concomitant herbal remedies, alternative medicines
Other illness
- Co morbid with other psychiatric illness including mood disorders and substance use disorders except tobacco
- Participants already diagnosed with Intellectual Disability Disorder, head injury
- Diagnosed with gastrointestinal disorders like Ulcerative colitis, Crohn's disease, Intestinal ulcers
- Current history of suicidal ideation, intention or attempts
Other
- Participants who are acutely symptomatic and are uncooperative for assessments
- Participants with sensory impairments
- Use of Donepezil, Rivastigmine, Memantine, Benzodiazepines
- Participants already on prucalopride
- Participants with contraindications to prucalopride
- Women who are pregnant or lactating
Who the study is looking for
- Diagnosed as schizophrenia by DSM 5 criteria using Structured Clinical Interview for DSM disorders
- Age between 18 to 55 years
- A minimum of one year of duration of illness
- Clinically stable with a stable therapeutic dose for at least 3 months prior to the recruitment
- Participants who can read and write English or Kannada
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| K S Hegde Medical Academy, Coordinator of this site? Confirm its status | Mangalore | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.